Navigating the Evolving Standards of Newly Diagnosed Multiple Myeloma Treatment: Exploring the Evidence on New Combination Strategies



Date & Location
Friday, August 30, 2024, 8:00 AM - Friday, August 29, 2025, 11:59 PM

Credits
AMA PRA Category 1 Credits™ (1.00 hours), ABIM MOC Part 2 (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Target Audience
Specialties - Hematology, Oncology
Professions - Advanced Practice Provider (APP), Non-Physician, Nurse, Physician

Overview
The goal of treatment for newly diagnosed multiple myeloma (NDMM) patients is achieving the deepest possible remission, which typically involves aiming for minimal residual disease negativity. Frontline therapy for NDMM is evolving to include novel induction regimens with anti-CD38 antibodies, which have been shown to yield improved depth of response after induction. These new frontline treatments vary in induction regimen composition and use of transplant, consolidation, and maintenance therapy. Patient- and disease-related factors (including high-risk genetics, frailty, and transplant eligibility), as well as treatment-related toxicities, complicate treatment decisions for health care providers (HCPs). In addition, supportive care interventions aimed at minimizing the risk of infection and other treatment-related adverse events (AEs) are critical for maintaining quality of life and ensuring that patients remain on therapy.

Registration
There are no fees for participating in and receiving CME credit for this online activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit, participants must complete the posttest and program evaluation. Certificates can be printed immediately.

This activity can be accessed using the following URL: https://www.mycme.com/courses/newly-diagnosed-multiple-myeloma-treatment-strategies-9646

For technical questions related to this activity, please contact RedMedEd at [email protected].
For questions regarding credit, contact University of Cincinnati at [email protected].

Objectives
As a result of participating in this activity, participants should be able to:

  1. Select new anti-CD38 antibody-based four-drug treatment combinations for NDMM patients based on the latest clinical trial efficacy and safety findings;
  2. Design a personalized treatment plan for NDMM patients, incorporating key evidence-based strategies to achieve disease remission and proactively mitigate and manage AEs

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Additional Information
Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Program Planners

RedMedEd
The RedMedEd planners have disclosed no relevant financial relationships.

University of Cincinnati Center for Continuous Professional Development/CME
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the University of Cincinnati, and Sanofi do not recommend the use of any agent outside the labeled indications.

Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the University of Cincinnati, or Sanofi. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.